Dec 5, 2022
Promising New Cancer Therapy Developed by Albert Einstein College of Medicine
Posted by Paul Battista in category: biotech/medical
Immune checkpoints are a normal part of the immune system. Their function is to prevent an immune response from being so powerful that it destroys healthy cells in the body. Immunotherapy drugs called immune checkpoint inhibitors, such as Keytruda and Opdivo, work by unleashing the immune system’s T cells to attack tumor cells. Their introduction a decade ago marked a major advance in cancer therapy. However, only 10% to 30% of treated patients experience long-term improvement.
Now, scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy in a study published in The Journal of Clinical Investigation (JCI) on November 15.
Continue reading “Promising New Cancer Therapy Developed by Albert Einstein College of Medicine” »